Pneumonia - Drug Pipeline Analysis and Market Forecasts to 2016

The Pneumonia Therapeutics Market is Forecast to Decline Until 2016

GlobalData’s analysis suggests that the global pneumonia market was worth $1.4 billion
in 2009. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 4.3% for
the next seven years to reach $1 billion by 2016. The projected decline rate is primarily
attributable to the patent expiries of Levaquin, Avelox and Zyvox by the end of the
forecast period. Increase in the treatment seeking population, the diagnosis population
and the ever-increasing development of bacterial resistance to marketed antibiotics are
expected to sustain the pneumonia market.

Pneumonia Market has Strong Competition Between the Several Marketed Products
GlobalData analyzed the current competitive landscape for pneumonia drugs and found
the competition to be strong. There are several marketed products for the treatment of
mild to severe pneumonia, which include cephalosoprins, macrolides, carbapenems,
penicillins, floroquinolones, tetracyclines and miscellaneous antibiotics. All treatments
are based on attempts to clinically cure and eradicate the pathogens. The monotherapy
regimens and combination therapies have satisfactory efficacy and safety profiles.
However, the patent expiries of major prescribed cephalosporins and Zyvox during the
forecast period have raised concerns, meaning that the pneumonia market will become
increasingly genericized. New entrants into the market will be forced to match or
exceed the efficacy and safety profiles of the currently marketed products.

For further information please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Pneumonia-Drug-Pipeline-
Analysis-and-Market-Forecasts-to-
2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_He
althcare

Weak Clinical Pipeline with Several Product-extension Molecules

GlobalData analyzed the pneumonia pipeline and found it to be weak. The pipeline for
pneumonia consists of 50 molecules currently in development for various disease
segments. Approximately 36% of the pneumonia pipeline is accounted for by product-
extensions. In Phase III alone, there are 12 product-extension molecules and five me-too
molecules including cell wall synthesis inhibitors and vaccines for immunoprophylaxis.
Phase III products with novel mechanisms of actions seem to be more promising for use
in the treatment of pneumonia caused by resistant organisms. A weak clinical pipeline
coupled with low unmet needs in the pneumonia market is expected to negatively
impact the market’s growth rate during the forecast period.

A Market with Low Unmet Need

GlobalData has found that the global pneumonia market is a not a lucrative market with
low levels of unmet need. The market is well served with several monotherapies and
combination therapies which target patients with different disease characteristics. The
efficacy and safety profiles of these products have improved over the years. Although
newer antimicrobials are capable of managing this potentially fatal condition, the use of
“correct-spectrum” antibiotics is the key as they can reduce the development of
antimicrobial resistance and maintaining efficacy for newer classes of drugs. Therefore,
the pneumonia market has low levels of unmet need that can be fulfilled by products
that target underserved patient populations and offer improved safety and efficacy
profiles.

GlobalData, the industry analysis specialist, has released a new report, “Pneumonia -
Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source
of information and analysis on the global pneumonia market. The report identifies the
key trends shaping and driving the global pneumonia market. The report also provides
insights on the prevalent competitive landscape and the emerging players expected to
cause significant shifts in the market positioning of the existing market leaders. Most
importantly, the report provides valuable insights on the pipeline products within the
global pneumonia sector.

For further information please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Pneumonia-Drug-Pipeline-
Analysis-and-Market-Forecasts-to-
2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_He
althcare

Or visit our report store: http://www.globaldata.com/reportstore

Contact Information:
Rajesh Gunnam
rgunnam@globaldata.com
+914066166782